Clinical Trial: Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT04822883) titled 'Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia' on March 12.

Brief Summary: The purpose of this study is to assess the safety and effects on electrical activity in the brain of an investigational drug (RL-007) for improving cognition in patients with schizophrenia

Study Type: Interventional

Condition: * Cognitive Impairment

* Schizophrenia

Intervention: * Drug: RL-007

Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing

* Drug: RL-007 Matching Placebo

Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing

Recruitment Status: Not Yet Recruiting

Sponsor: Recognify Life Sciences

Information provid...